NEW YORK (TheStreet) -- The race continues for biotechnology companies to gain Food and Drug Administration approval for their Ebola and Zika disease vaccines and Inovio Pharmaceuticals (INO) - Get Reportconsiders itself a developmental leader.

Including vaccines for Zika and Ebola, Inovio is optimistic about its current research, even if some critics believe its pipeline of drugs is spreading the company too thin.

"Getting critical validation through our testing, the FDA approval for these trials, whether it's phase one or phase three, have been an amazing development for us," Inovio CEO Dr. Joseph Kim said on CNBC's "Power Lunch" this afternoon.

The San Diego, CA-based bio-pharmaceutical company, is developing immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. Currently testing 14 unique drugs, with none of them commercially available, Inovio is completing FDA-required trials for approval. The company's most developed drug, a treatment for cervical dysplasia, is now in FDA phase three testing.

"We have 200-plus dedicated scientists and vaccine developers going to work every day in advancing these programs," Kim said.

Despite being a smaller company, through partnerships with larger corporations and utilizing their resources they "think more in terms of leap-frogging the technology," Kim added.

For treating the Zika virus, Inovio will soon finish its first 40-subject study and are "planning to go into a field study very rapidly to test the vaccine," Kim notes. He also said Inovio is "in the process of completing our first 75-subject study" for Ebola, where they "we were able to generate very high levels of Ebola-specific antibodies that can protect the patients." Research papers for peer review on Inovio's Ebola vaccine are forthcoming from the rising biotechnology company.

Shares of Inovio closed up by 0.54% to $11.26 on Tuesday. 

Separately, TheStreet Ratings team rates Inovio as a "sell" with a ratings score of D. 

This is driven by a number of negative factors, which TheStreet Ratings believes should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks TheStreet Ratings team covers. Among the areas TheStreet Ratings feels are negative, one of the most important has been weak operating cash flow.

TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author. 

You can view the full analysis from the report here: INO

Image placeholder title